Steven F. Huege, MD

Assistant Clinical Professor of Psychiatry
Section of Geriatric Psychiatry
Associate Program Director, Geriatric Psychiatry Fellowship Program
Perelman School of Medicine at the University of Pennsylvania


Dr. Huege is an assistant clinical professor of psychiatry at the University of Pennsylvania. He received his undergraduate training at Duke University and attended medical school at the University of Texas- Southwestern Medical School. He subsequently completed his psychiatric residency at Thomas Jefferson University Hospital, where he also served as chief resident. Dr. Huege completed a fellowship in geriatric psychiatry at the University of Pennsylvania. He is board certified in adult and geriatric psychiatry. Dr. Huege was a Fellow with the American Association for Geriatric Psychiatry (AAGP) and was selected as an AAGP Member-in-Training Board member.

Academic Interests

Dr. Huege serves on the faculty of the Perelman School of Medicine at the University of Pennsylvania and is active in the training and mentoring of geriatric fellows. His interests include training geriatric medicine specialists to better understand and treat mental disorders in their patients, and he serves as associate program director for Penn’s geriatric psychiatry fellowship program. Dr. Huege is also active with AAGP and has participated in AAGP public policy events and committees.

Clinical Interests

As a psychiatrist with additional training in geriatric psychiatry, Dr. Huege specializes in the treatment of older adults with chronic and new-onset mental illness. Areas of expertise include: Alzheimer’s disease, other dementias- Fronto-Temporal, Lewy Body, and mood and psychotic disorders in the elderly. He also conducts dynamically oriented psychotherapy with adult and geriatric patients.

At the Philadelphia VAMC, Dr. Huege consults at the VA Community Living Center, formerly the VA Nursing Home Care Unit, and evaluates and treats patients in the geriatric medicine clinic.


Dr. Huege is involved in clinical trials at Penn to evaluate novel treatments for dementia, with special emphasis on biomarkers and natural/herbal compounds.

More Information

Back to Top